º«¹úÂãÎè

Diamond Therapeutics Signs Agreement with º«¹úÂãÎè for Research on Low-Dose LSD

Published: 4 February 2021

TORONTO, Feb. 4, 2021 /CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement...

R+I Services during º«¹úÂãÎè COVID-19 Closure

Published: 17 March 2020

Sent on behalf of Martha Crago, Vice-Principal (Research and Innovation)...

Reminder: Canada Research Continuity Emergency Fund (CRCEF)

Published: 10 November 2020

This is a reminder to all principal investigators to complete their Canada Research Continuity Emergency Fund Stage 3 claims as soon as possible.

Pages

Back to top